About
Immuno-oncology
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyBoston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
433
By Phase
PHASE3: 1PHASE1: 2
By Status
TERMINATED: 1ACTIVE_NOT_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT04786964Lead Sponsor
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
PHASE3Terminated
25 participants
Started: Dec 8, 2021 · Completed: Dec 30, 2023
NCT03212404Lead Sponsor
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
PHASE1Active, not recruiting
272 participants
Started: Sep 20, 2017 · Completed: Dec 31, 2025
NCT02926768Lead Sponsor
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
PHASE1Completed
136 participants
Started: Sep 30, 2016 · Completed: Jun 30, 2022
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...